{
  "id": "5884c72fe56acf517600000f",
  "type": "factoid",
  "question": "What molecule is targeted by Avelumab?",
  "ideal_answer": "Avelumab is a monoclonal antibody that binds programmed death-ligand 1 (PD-L1).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27172898",
    "http://www.ncbi.nlm.nih.gov/pubmed/27350882",
    "http://www.ncbi.nlm.nih.gov/pubmed/26014098",
    "http://www.ncbi.nlm.nih.gov/pubmed/27815822",
    "http://www.ncbi.nlm.nih.gov/pubmed/27544053",
    "http://www.ncbi.nlm.nih.gov/pubmed/27490642",
    "http://www.ncbi.nlm.nih.gov/pubmed/27592805",
    "http://www.ncbi.nlm.nih.gov/pubmed/26880697",
    "http://www.ncbi.nlm.nih.gov/pubmed/26921031",
    "http://www.ncbi.nlm.nih.gov/pubmed/26477470",
    "http://www.ncbi.nlm.nih.gov/pubmed/27716622",
    "http://www.ncbi.nlm.nih.gov/pubmed/27196116"
  ],
  "snippets": [
    {
      "text": "Several drugs targeting PD-1 (pembrolizumab and nivolumab) or PD-L1 (atezolizumab, durvalumab, and avelumab) have been approved or are in the late stages of development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27196116",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We then focus on the recent breakthrough work concerning the structural basis of the PD-1/PD-Ls interaction and how therapeutic antibodies, pembrolizumab targeting PD-1 and avelumab targeting PD-L1, compete with the binding of PD-1/PD-L1 to interrupt the PD-1/PD-L1 interaction. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815822",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490642",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In addition, we assessed the safety and biological activity of a human anti-PD-L1 antibody (Avelumab) in chronically SIV-infected rhesus macaques.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490642",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We assessed treatment with avelumab, an anti-PD-L1 monoclonal antibody, in patients with stage IV Merkel cell carcinoma that had progressed after cytotoxic chemotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27592805",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716622",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Here, we describe the efficacy of NIR-PIT, using fully human IgG1 anti-PD-L1 monoclonal antibody (mAb), avelumab, conjugated to the photo-absorber, IR700DX, in a PD-L1 expressing H441 cell line, papillary adenocarcinoma of lung.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716622",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In conclusion, the anti-PD-L1 antibody, avelumab, is suitable as an APC for NIR-PIT. Furthermore, NIR-PIT with avelumab-IR700 is a promising candidate of the treatment of PD-L1-expressing tumors that could be readily translated to humans.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716622",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26014098",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "MSB0010718C (designated avelumab) is a fully human IgG1 anti-PD-L1 mAb.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26014098",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These studies thus provide an additional mode of action for an anti-PD-L1 mAb and support the rationale for further studies to enhance avelumab-mediated ADCC activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26014098",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We then focus on the recent breakthrough work concerning the structural basis of the PD-1/PD-Ls interaction and how therapeutic antibodies, pembrolizumab targeting PD-1 and avelumab targeting PD-L1, compete with the binding of PD-1/PD-L1 to interrupt the PD-1/PD-L1 interaction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815822",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In addition, mesothelioma tumor cells are susceptible to ADCC by the anti-PD-L1 antibody avelumab..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27544053",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921031",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In addition, we assessed the safety and biological activity of a human anti-PD-L1 antibody (Avelumab) in chronically SIV-infected rhesus macaques.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27490642",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Different mechanisms to prevent immunologic escape have been characterized during the last years; in particular the PD-1/PD-L1 inhibitors pembrolizumab, avelumab, durvalumab and atezolizumab have shown early sign of efficacy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26880697",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "programmed death-ligand 1, PD-L1"
}